This study will assess the effect of partially hydrolyzed, whey-based infant formulas on growth and gastrointestinal tolerance in healthy term infants.
Written informed consent has been obtained from at least one parent (or other legally acceptable representative [LAR]), if applicable)
Infant gestational age ≥37 completed weeks
Infant birth weight of ≥2.5 kg and ≤4.5 kg
Singleton birth
Chronic infectious, metabolic, genetic illness or other disease, including any condition that impacts feeding or growth
Major congenital or chromosomal abnormality known to affect growth (e.g., congenital heart disease, cystic fibrosis)
Maternal medical conditions known to affect infant growth (e.g., untreated preeclampsia or gestational diabetes)
Infants with special dietary needs other than standard infant formula